Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials
Ryan C, Leonardi CL, Krueger JG et al.
Rofecoxib, a nonsteroidal anti-inflammatory drug, is a prime example of a drug that continued to be prescribed for a considerable length of time – in this case to >80 million patients – despite warnings from preliminary data showing increased cardiovascular (CV) risks associated with the drug. A randomized controlled trial of 2586 patients ultimately demonstrated an excess of thrombotic events with rofecoxib relative to placebo, and the drug was withdrawn.
» Read an expert review of this paper